Hematology / Oncology / Cancer Center / Breast Clinic

Medicine & Life Sciences

1. Breast Neoplasms 100%
2. Multiple Myeloma 63%
3. Neoplasms 63%
4. Therapeutics 52%
5. Survival 46%
6. Trastuzumab 39%
7. Drug Therapy 38%
8. B-Cell Chronic Lymphocytic Leukemia 27%
9. Lenalidomide 25%
10. Progression-Free Survival 24%
11. Melanoma 22%
12. human ERBB2 protein 21%
13. Paclitaxel 20%
14. Bortezomib 20%
15. Safety 18%
16. Acute Myeloid Leukemia 18%
17. Prostatic Neoplasms 17%
18. Aromatase Inhibitors 17%
19. Dexamethasone 17%
20. Waldenstrom Macroglobulinemia 17%
21. Renal Cell Carcinoma 17%
22. Recurrence 17%
23. Clinical Trials 17%
24. pembrolizumab 15%
25. T-Lymphocytes 15%
26. Non-Small Cell Lung Carcinoma 15%
27. Kinesin 15%
28. Anthracyclines 14%
29. Letrozole 14%
30. PCI 32765 14%
31. Rituximab 14%
32. Lymphoma 14%
33. taxane 14%
34. Immunotherapy 14%
35. Alaska Natives 14%
36. Cyclophosphamide 14%
37. Mutation 13%
38. Confidence Intervals 13%
39. Cisplatin 12%
40. Non-Hodgkin's Lymphoma 12%
41. Docetaxel 12%
42. Lapatinib 11%
43. Doxorubicin 11%
44. pomalidomide 11%
45. Tamoxifen 11%
46. Disease-Free Survival 11%
47. Transplants 11%
48. Bone Marrow 11%
49. B-Cell Lymphoma 10%
50. Placebos 10%
51. Estrogen Receptors 10%
52. Quality of Life 10%
53. Bevacizumab 10%
54. Glioma 10%
55. Breast 10%
56. Cell Transplantation 10%
57. Pharmaceutical Preparations 10%
58. Population 9%
59. B-Lymphocytes 9%
60. Genes 9%
61. Incidence 9%
62. Biomarkers 9%
63. gemcitabine 9%
64. Guidelines 9%
65. Allogeneic Cells 9%
66. Lymphoma, Large B-Cell, Diffuse 9%
67. Neoplasm Metastasis 9%
68. Radiotherapy 8%
69. Appointments and Schedules 8%
70. Sarcoma 8%
71. Myelodysplastic Syndromes 8%
72. Primary Myelofibrosis 8%
73. Capecitabine 8%
74. Adjuvant Chemotherapy 8%
75. Microtubules 8%
76. Carboplatin 8%
77. Triple Negative Breast Neoplasms 8%
78. ixabepilone 8%
79. Taxoids 8%
80. Thalidomide 7%
81. Colorectal Neoplasms 7%
82. Castration 7%
83. Mortality 7%
84. Plasma Cells 7%
85. atezolizumab 7%
86. Hormones 7%
87. Vaccines 7%
88. Pharmacokinetics 7%
89. Lung Neoplasms 7%
90. Maximum Tolerated Dose 7%
91. Neutropenia 7%
92. Fluorescence In Situ Hybridization 7%
93. Cytogenetics 6%
94. Immunoglobulin Light-chain Amyloidosis 6%
95. Follicular Lymphoma 6%
96. Vomiting 6%
97. Glioblastoma 6%
98. Central Nervous System 6%
99. Circulating Tumor DNA 6%